Devy L - Search Results

1

Improved quantification of angiogenesis in the rat aortic ring assay.

Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, Noël A, Foidart JM. Blacher S, et al. Among authors: devy l. Angiogenesis. 2001;4(2):133-42. doi: 10.1023/a:1012251229631. Angiogenesis. 2001. PMID: 11806245 Free article.

2

Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis.

Masson V VÉ, Devy L, Grignet-Debrus C, Bernt S, Bajou K, Blacher S, Roland G, Chang Y, Fong T, Carmeliet P, Foidart JM, Noël A. Masson V VÉ, et al. Among authors: devy l. Biol Proced Online. 2002 Oct 28;4:24-31. doi: 10.1251/bpo30. Biol Proced Online. 2002. PMID: 12734572 Free PMC article.

3

MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression.

Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A. Sounni NE, et al. Among authors: devy l. FASEB J. 2002 Apr;16(6):555-64. doi: 10.1096/fj.01-0790com. FASEB J. 2002. PMID: 11919158

4

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.

Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Nöel A, Foidart JM. Devy L, et al. FASEB J. 2002 Feb;16(2):147-54. doi: 10.1096/fj.01-0552com. FASEB J. 2002. PMID: 11818362

5

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.

Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V. Deroanne CF, et al. Among authors: devy l. Oncogene. 2002 Jan 17;21(3):427-36. doi: 10.1038/sj.onc.1205108. Oncogene. 2002. PMID: 11821955

6

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.

Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noël A. Hajitou A, et al. Among authors: devy l. FASEB J. 2002 Nov;16(13):1802-4. doi: 10.1096/fj.02-0109fje. Epub 2002 Sep 19. FASEB J. 2002. PMID: 12354694

7

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A. Devy L, et al. FASEB J. 2004 Mar;18(3):565-7. doi: 10.1096/fj.03-0462fje. Epub 2004 Jan 20. FASEB J. 2004. PMID: 14734647

8

Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.

Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noël A. Maquoi E, et al. Among authors: devy l. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4038-47. doi: 10.1158/1078-0432.CCR-04-0125. Clin Cancer Res. 2004. PMID: 15217936 Free article.

9

Emerging roles for proteinases in cancer.

Noël A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A, Foidart JM. Noël A, et al. Among authors: devy l. Invasion Metastasis. 1997;17(5):221-39. Invasion Metastasis. 1997. PMID: 9876217 Free article. Review.

10

Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.

Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noël A. Hajitou A, et al. Among authors: devy l. Cancer Res. 2001 Apr 15;61(8):3450-7. Cancer Res. 2001. PMID: 11309307 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page